BACKGROUND: Allergen-specific immunotherapy via the skin targets a tissue rich in antigen-presenting cells, but can be associated with local and systemic side effects. Allergen-polysaccharide neoglycogonjugates increase immunization efficacy by targeting and activating dendritic cells via C-type lectin receptors and reduce side effects. OBJECTIVE: We investigated the immunogenicity, allergenicity, and therapeutic efficacy of laminarin-ovalbumin neoglycoconjugates (LamOVA). METHODS: The biological activity of LamOVA was characterized in vitro using bone marrow-derived dendritic cells. Immunogenicity and therapeutic efficacy were analyzed in BALB/c mice. Epicutaneous immunotherapy (EPIT) was performed using fractional infrared laser ablation to generate micropores in the skin, and the effects of LamOVA on blocking IgG, IgE, cellular composition of BAL, lung, and spleen, lung function, and T-cell polarization were assessed. RESULTS: Conjugation of laminarin to ovalbumin reduced its IgE binding capacity fivefold and increased its immunogenicity threefold in terms of IgG generation. EPIT with LamOVA induced significantly higher IgG levels than OVA, matching the levels induced by s.c. injection of OVA/alum (SCIT). EPIT was equally effective as SCIT in terms of blocking IgG induction and suppression of lung inflammation and airway hyperresponsiveness, but SCIT was associated with higher levels of therapy-induced IgE and TH2 cytokines. EPIT with LamOVA induced significantly lower local skin reactions during therapy compared to unconjugated OVA. CONCLUSION: Conjugation of ovalbumin to laminarin increased its immunogenicity while at the same time reducing local side effects. LamOVA EPIT via laser-generated micropores is safe and equally effective compared to SCIT with alum, without the need for adjuvant.
BACKGROUND: Allergen-specific immunotherapy via the skin targets a tissue rich in antigen-presenting cells, but can be associated with local and systemic side effects. Allergen-polysaccharide neoglycogonjugates increase immunization efficacy by targeting and activating dendritic cells via C-type lectin receptors and reduce side effects. OBJECTIVE: We investigated the immunogenicity, allergenicity, and therapeutic efficacy of laminarin-ovalbumin neoglycoconjugates (LamOVA). METHODS: The biological activity of LamOVA was characterized in vitro using bone marrow-derived dendritic cells. Immunogenicity and therapeutic efficacy were analyzed in BALB/c mice. Epicutaneous immunotherapy (EPIT) was performed using fractional infrared laser ablation to generate micropores in the skin, and the effects of LamOVA on blocking IgG, IgE, cellular composition of BAL, lung, and spleen, lung function, and T-cell polarization were assessed. RESULTS: Conjugation of laminarin to ovalbumin reduced its IgE binding capacity fivefold and increased its immunogenicity threefold in terms of IgG generation. EPIT with LamOVA induced significantly higher IgG levels than OVA, matching the levels induced by s.c. injection of OVA/alum (SCIT). EPIT was equally effective as SCIT in terms of blocking IgG induction and suppression of lung inflammation and airway hyperresponsiveness, but SCIT was associated with higher levels of therapy-induced IgE and TH2 cytokines. EPIT with LamOVA induced significantly lower local skin reactions during therapy compared to unconjugated OVA. CONCLUSION: Conjugation of ovalbumin to laminarin increased its immunogenicity while at the same time reducing local side effects. LamOVA EPIT via laser-generated micropores is safe and equally effective compared to SCIT with alum, without the need for adjuvant.
Authors: Leigh Willard; Anuj Ranjan; Haiyan Zhang; Hassan Monzavi; Robert F Boyko; Brian D Sykes; David S Wishart Journal: Nucleic Acids Res Date: 2003-07-01 Impact factor: 16.971
Authors: Agostinho Carvalho; Gloria Giovannini; Antonella De Luca; Carmen D'Angelo; Andrea Casagrande; Rossana G Iannitti; Giovanni Ricci; Cristina Cunha; Luigina Romani Journal: Cell Mol Immunol Date: 2012-04-30 Impact factor: 11.530
Authors: Richard Weiss; Michael Hessenberger; Sophie Kitzmüller; Doris Bach; Esther E Weinberger; Wolf D Krautgartner; Cornelia Hauser-Kronberger; Bernard Malissen; Christof Boehler; Yogeshvar N Kalia; Josef Thalhamer; Sandra Scheiblhofer Journal: J Control Release Date: 2012-06-29 Impact factor: 9.776
Authors: D Bach; R Weiss; M Hessenberger; S Kitzmueller; E E Weinberger; W D Krautgartner; C Hauser-Kronberger; C Boehler; J Thalhamer; S Scheiblhofer Journal: Allergy Date: 2012-09-05 Impact factor: 13.146
Authors: Enas Mahmoud Amer; Saber H Saber; Ahmad Abo Markeb; Amal A Elkhawaga; Islam M A Mekhemer; Abdel-Naser A Zohri; Turki S Abujamel; Steve Harakeh; Elham A Abd-Allah Journal: Molecules Date: 2021-04-07 Impact factor: 4.411
Authors: Sandra Scheiblhofer; Stephan Drothler; Werner Braun; Reinhard Braun; Maximilian Boesch; Richard Weiss Journal: Vaccine Date: 2021-06-26 Impact factor: 4.169